nilutamide (Nilandron)

Indications

• used in combination with LHRH agonist for treatment of metastatic prostate cancer

Dosage

• 300 mg PO QD for one month, then
• 150 mg PO QD

Pharmacokinetics

• well obsorbed orally
• peak serum levels in 1-4 hours after oral dosing
• 80% protein bound
• metabolized extensively by the liver
• 60% excreted in the urine as metabolites
• elimination 1/2 life is 38-60 hours

elimination via liver

1/2life = 38-60 hours

protein binding = 80 %

Adverse effects

• hot flashes
• gynecomastia
• nausea/vomiting
• abnormal liver function tests
• visual delayed adaptation to darkness
• interstitial pneumonitis
• pruritus
• alcohol intolerance

Mechanism of action

• non-steroidal androgen receptor antagonist

More general terms

• androgen receptor antagonist
• antineoplastic endocrine agent

Additional terms

• prostate cancer

Database

• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=4493